As a valued Relias Media subscriber, you can find the latest issue of your publication online. The articles below provide timely strategies and research for healthcare providers:
In patients without an indication for anticoagulation undergoing transcatheter aortic valve replacement, treatment with edoxaban did not significantly affect the incidence of leaflet thrombosis as detected by CT scans.
A study of a low-sodium diet for chronic, stable heart failure patients after one year showed no difference in hard clinical outcomes, but the degree of sodium restriction was modest.
In a review of COVID-19-associated acute myocarditis, investigators learned it is a rare complication that can occur without concomitant pneumonia, and frequently presents as cardiogenic shock. With supportive therapy, the short-term mortality rate is low.
In patients age 80 years and older with atrial fibrillation who were not considered for oral anticoagulants because of serious comorbidities, one-quarter of the recommended daily dose of edoxaban was superior to placebo for preventing thromboembolic events.
Researchers found the Canadian Syncope Risk Score accurately predicts which patients are low risk for discharge. However, since it is largely driven by the physician’s final risk classification at ED discharge, the score’s clinical utility is uncertain.
Financial Disclosure: None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
